GLP-1 & Metabolic
Tirzepatide Regain: 1.04 kg a Month, 15 Months Modelled
Tirzepatide and semaglutide users regained 1.04 kg a month after stopping. The 15 months to baseline is an extrapolation, not an observation.
Semaglutide vs Surgery: Same Stiffness Drop, Less Fat Loss
Semaglutide cut liver fat about half as much as sleeve gastrectomy over 72 weeks, and liver stiffness fell by the same relative amount.
GLP-1 in Serious Mental Illness: 764,115 Matched Pairs
GLP-1 initiation was linked to lower four-year mortality than SGLT2 inhibitors in serious mental illness, and the absolute gap was larger there.
GLP-1 Below BMI 27: Benefit With Little Weight to Lose
GLP-1 receptor agonists cut coded heart failure in type 2 diabetes with a BMI under 27, where there is almost no weight left to lose.
Tirzepatide Plus TOFA: More Than Additive in Obese Mice
Tirzepatide works by cutting food intake. A 2026 Science Advances paper reports an oral molecule that cuts fat without touching intake, and adds to it.
Tirzepatide vs Semaglutide: Liver Outcomes Are Level
Tirzepatide dropped more BMI than semaglutide over 17 months, and hard liver outcomes came out identical: 4.05 versus 4.04 events per 1000 person-years.
Tirzepatide and HFpEF: What 3,308 Matched Patients Show
Tirzepatide-treated men and women with HFpEF differed little on cardiovascular outcomes. The authors say the design cannot show effectiveness by sex.
Avexitide: a GLP-1 Blocker Cuts Hypoglycaemia by 55%
Avexitide blocks the GLP-1 receptor instead of activating it. Amylyx reports a 55% cut in hypoglycaemic events in a 78-participant phase 3 trial.
GLP-1 and Mitochondria: A 2026 Review Maps the Axis
GLP-1 drugs touch mitochondrial biogenesis, dynamics and mitophagy. A 2026 Aging Cell review asks how much of that is the receptor, not weight loss.
Semaglutide Cut hsCRP 37.8% in SELECT, Before Weight Loss
Semaglutide lowered hsCRP by 37.8% in SELECT, and the drop appeared by week 4, before major weight loss and also in people who lost no weight.